Brenipatide
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obesity
Conditions
Obesity, Overweight
Trial Timeline
Mar 1, 2026 → Feb 1, 2027
NCT ID
NCT07476118About Brenipatide
Brenipatide is a phase 1 stage product being developed by Eli Lilly for Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07476118. Target conditions include Obesity, Overweight.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07476118 | Phase 1 | Recruiting |
Competing Products
20 competing products in Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 52 |
| MK0557 | Merck | Phase 3 | 77 |
| AMG 786 | Amgen | Phase 1 | 32 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| Tirzepatide | Eli Lilly | Phase 2 | 52 |
| exenatide + Placebo | Eli Lilly | Approved | 85 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 28 |
| PG-102 | Rani Therapeutics | Phase 1 | 25 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 33 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 33 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 44 |
| Tirzepatide | Eli Lilly | Approved | 85 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 23 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 85 |
| Micafungin | Astellas Pharma | Approved | 85 |